trial

A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

NCTId NCT05145413
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 396 (actual)
Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Primary completion 2025-03-19
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
396 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2021-11-12
Primary completion
2025-03-19
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Xanomeline-trospium (Cobenfy)

Sponsors

Karuna Therapeutics, Inc., a Bristol Myers Squibb companyLead Sponsor

Sites

166 total
Phoenix, United StatesPhoenix, United StatesLittle Rock, United StatesLittle Rock, United StatesAnaheim, United StatesBellflower, United StatesCerritos, United StatesCosta Mesa, United StatesCulver City, United StatesGarden Grove, United StatesLa Habra, United StatesLafayette, United States

Linked catalysts

1
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inade — primary completion2025-03-19

Facts & assertions

4 sourced
Enrollment
396
Phase
PHASE3
Primary Completion Date
2025-03-19
Status
COMPLETED
relationships
The graph out of here
drug
Xanomeline-trospium (Cobenfy)
drug
lead_sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
company
indication
Schizophrenia
indication
Schizophrenia
indication